In conclusion, treatment with the TNF-alpha inhibitor adalimumab demonstrably leads to a significant decrease in C-reactive protein levels in patients with HS, which confirms its systemic anti-inflammatory effect as validated by many studies we discussed in our article. This evidence concerns the gene TNF and histiocytic sarcoma.